Amydis Diagnostics
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
9310 Athena Cir Ste 100, La Jolla, Calif...Website
www.amydis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Amydis Diagnostics
Amydis is a leader in developing innovative ocular tracers that facilitate the digital detection and monitoring of disease-related molecular biomarkers using standard ocular imaging cameras. Their pioneering technology aims to accelerate diagnosis, enhance clinical testing of new therapeutics, and transform treatment approaches for diseases affecting the brain, eye, and heart. The company focuses on precision healthcare powered by artificial intelligence, targeting healthcare professionals and researchers in the medical field. Through their advancements, Amydis seeks to improve human life by providing eye-opening innovations in diagnostics.Explore more
Amydis Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amydis Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Amydis Diagnostics launches new products
Click to see if Amydis Diagnostics had a recent Job posting/layoffs
Earning: See what the market has to say on Amydis Diagnostics recently announced quarterly report
Check if Amydis Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Amydis Diagnostics has new funding data
Check out if Amydis Diagnostics is spiking on competitors!
Amydis Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Amydis Diagnostics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Amydis Diagnostics as Masked Content
Find more new buyers
Compare Similar Companies to Amydis Diagnostics
Compare insights from companies similar to Amydis Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Amydis Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Amydis Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Amydis Diagnostics.
Amydis Diagnostics Tech Stack
A closer look at the technologies used by Amydis Diagnostics
See more technologies
Amydis Diagnostics News & Media
Amydis to Present First Ocular Tracer Designed to Detect Transthyretin Amyloidosis (ATTR) at AAOOP Conference
Amydis is developing a topical eye test to potentially transform early diagnosis of amyloidosis and enable more people to benefit from available drugsAmydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today announced initiation of enrollment of patients with cerebral amyloid angiopathy (CAA), an age-associated disease in which a protein called amyloid beta (Aβ) builds up on the walls of the arteries in the brain increasing the risk for stroke and dementia. CAA develops in upAmydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today announced it has been awarded a third grant for $1.5M from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will support the first-in-human study of a retinal tracer targeting alpha-synuclein (ASYN) in a Prospective Randomized Open, Blinded Endpoint (PROBE) clinical study whiAmydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD
SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH). The grant supports the development of a novel small-molecule retinal tracer targeting the biomarker TAR DNA-binding protein 43 (TDP-43) in patients with amyotrophic lateral
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Amydis Diagnostics
Sign Up For FreeTo access detailed company insights
Amydis is a leader in developing innovative ocular tracers that facilitate the digital detection and monitoring of disease-related molecular biomarkers using standard ocular imaging cameras. Their pioneering technology aims to accelerate diagnosis, enhance clinical testing of new therapeutics, and transform treatment approaches for diseases affecti... Read More
